ASCO Presenter Urges KRAS Testing for All Colorectal Cancer Patients Before Erbitux Treatment | GenomeWeb
CHICAGO (GenomeWeb News) — Results from a large, multinational prospective clinical trial have shown that patients with metastatic colorectal cancer whose tumor carries the wild-type version of the KRAS gene are much more likely than patients with the mutated form of the gene to benefit from the monoclonal antibody Erbitux.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.